 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
Octreotide is an investigational synthetic peptide exhibiting actions similar to those of endogenous somatostatin. It has a longer half-life than the native hormone and can be administered by subcutaneous injection. Octreotide inhibits the secretion of growth hormone and numerous regulatory peptides of the gastroenteropancreatic system. Trials evaluating the clinical utility of octreotide indicate efficacy in the management of symptoms associated with acromegaly and hypersecretory neuroendocrine tumors, and in the control of nontumoral secretory diarrheas. Octreotide therapy is well tolerated. This agent should prove useful in the symptomatic control of a number of rare hypersecretory disorders.
This article has been cited by other articles:
|
|
 |
|
  P. J. Gilbar The role of octreotide in symptom management in oncology and palliative care Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3): 81 - 91. [Abstract] [PDF]
|
|
|
|
 |
|
 G. H. Rosen Somatostatin and Its Analogs in the Short Bowel Syndrome Nutr Clin Pract, April 1, 1992; 7(2): 81 - 85. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Bennett and R. D. Allen High-Technology Home Pharmacotherapy, II: An Overview of the Newest Home Therapies Journal of Pharmacy Practice, January 1, 1990; 3(1): 40 - 47. [Abstract] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
